References
- Helms J, Kremer S., Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med 2020; 382:22682270.
- Oxley T., Mocco J., Majidi S., et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020;382:e60
- Rábano-Suárez P., Bermejo-Guerrero L., Méndez-Guerrero A., et al. Generalized myoclonus in COVID-19. Neurology 2020;95(6): e767-e772
- Mancuso E, Tanzi G. Paradoxical Reactions to Benzodiazepines: Literature Review and Treatment Options. Pharmacotherapy. 2004;24(9):1177-85.
- Lee H, Lee J. Lance-Adams Syndrome. Annals of Rehabilitation Medicine. 2011;35:939.
- Rice J, Nagle S, Randall J, et al. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Curr Treat Options Neurol. 2019;21(8):40.
- Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukaemia. Cancer Discov. 2018;8:958–71.
- Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473‐4
- Kabaka N, Taskin E, Aydin M. Segmental myoclonus as the presenting symptom of an acute disseminated encephalomyelitis: a case report. Eur J Paediatr Neurol. 2006;10(1):45-8
- Siddiqui HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A ClinicalTherapeutic Staging Proposal. J Heart Lung Transplant. 2020 May;39(5):405-7.